Streetbeat News

LUMO

Lumos Pharma, Inc.

https://www.lumos-pharma.com

Industry

Biotechnology

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

Open

4.34

Mkt cap

37M

Volume

102K

High

4.39

P/E Ratio

-1.01

52-wk high

4.58

Low

4.30

Div yield

N/A

52-wk low

1.37

Monteverde & Associates PC is investigating the merger of Lumos Pharma Inc. with Double Point Ventures LLC. The deal involves Double Point Ventures acquiring Lumos Pharma's shares for $4.25 each, plus a Contingent Value Right per share.

Portfolio Pulse from

November 06, 2024 | 8:00 pm

Lumos Pharma (NASDAQ:LUMO) has been analyzed by 5 analysts, showing a range of ratings from bullish to bearish. Recent analyst actions include lowered price targets and ratings, with an average 12-month price target of $13.1, down from $23.00. The company faces financial challenges, including a decline in revenue growth and negative profitability metrics.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 7:00 pm

HC Wainwright & Co. has downgraded Lumos Pharma from Buy to Neutral and significantly lowered its price target from $28 to $4.25.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 6:53 pm

Jones Trading has downgraded Lumos Pharma from Buy to Hold and significantly lowered its price target from $20 to $4.25.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 9:09 pm

Lumos Pharma shares surged after announcing a go private placement with Double Point Ventures, offering $4.25 per share in cash.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 1:20 pm

Trading for LUMO was halted and has now resumed. The halt was updated at 8:25 AM ET, indicating a temporary pause in trading activities for the company.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:25 pm

Lumos Pharma has entered into a go-private agreement with Double Point Ventures, offering $4.25 cash per share in a tender offer.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:03 pm

Trading of Lumos Pharma shares has been halted pending news. This typically indicates that significant information is about to be released, which could impact the stock price.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:56 am

Trading for a company has been halted at 7:55 a.m. ET due to pending news. This could indicate significant upcoming announcements that may impact the stock price.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:55 am

HC Wainwright & Co. has reiterated its Buy rating for Lumos Pharma, maintaining a price target of $28. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 3:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.